People with Alzheimer’s disease are more likely to have drusen in their peripheral retinas, as well as unusual vascular characteristics, researchers believe.
Editor’s Note: Ophthalmology Times is pleased to announce Peter H.
Elizabeth Atchison, MD, senior fellow, Rush University and Illinois Retina Associates Chicago, is the first-place honoree of the Ophthalmology Times Research Scholar Honoree Program. Below is her abstract:
What's in a name? When it comes to ophthalmology, a lot. Persistent hyperplastic primary vitreous—an old name that addressees only the status of the primary vitreous—needs updating, said Michael Trese, MD.
Throughout the body, any source of cellular damage (e.g., inflammation, infection, smoking, or high blood sugar) can liberate reactive oxygen species and set in motion an oxidative stress chain reaction that ultimately leads to tissue dam
Central serous retinopathy (CSR) is a heterogeneous disease with different phenotypes. Multimodal imaging is one way to understand more about the pathogenesis of the disease, and can be used to guide treatment.
Editor’s Note: Welcome to “Eye Catching: Let's Chat,” a blog series featuring contributions from members of the ophthalmic community.
Retinal vein occlusions (RVOs) are a frequent cause of retinal vascular disease in patients older than 50 years.
With advances in local treatment of uveitis over the past decade, the therapeutic armamentarium has increased from depot injections with short-lasting activity to long-term treatments, said Thomas A. Albini, MD.
Compared with intravitreous ranibizumab, the decreases in the plasma-free VEGF levels were greater with intravitreous aflibercept and bevacizumab in patients with diabetic macular edema.